A Comprehensive COVID-19 Treatments Review

By Staff Writer

October 20, 2023

COVID-19 Treatments: A Race Against Time

The COVID-19 pandemic has led to an urgent need for effective treatments of this unknown disease. As of January 2023, there have been over 620 million confirmed cases of the virus and more than six-and-a-half million deaths worldwide. In the UK alone, the numbers are staggering with more than 24 million cases and nearly 200,000 deaths during this time.

COVID-19 Treatments Review

Various treatments have been developed and used to help people who have been hospitalised due to COVID-19 or are at high risk of needing hospitalisation. These include casirivimab/imdevimab, tocilizumab, remdesivir, baricitinib, and baricitinib with remdesivir for hospitalised patients. For patients at high risk, treatments include casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, remdesivir, sotrovimab, and tixagevimab/cilgavimab.

Evaluating Clinical Efficacy and Cost-effectiveness

The objective of this study was to summarise the current knowledge related to the clinical efficacy of these interventions and to conduct an economic evaluation that estimates the cost-effectiveness of each intervention against standard of care (SoC).

Despite the urgency, these treatments have not received positive guidance from the National Institute of Health and Care Excellence (NICE) before being routinely used. As the pandemic subsides, there is more need for a formal evaluation of these treatments.

The results of the study, however, should be treated with caution due to changes in the conditions when the pivotal studies were undertaken and the current conditions in terms of the SoC, the percentage of people who have been vaccinated and a change in the dominant SARS-CoV-2 variant.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.